Showing 1231-1240 of 10816 results for "".
Guselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.Hair Today
https://practicaldermatology.com/conferences/scale-2023/hair-today/20204/Joel L. Cohen, MD, and Doris Day, MD, discuss the latest advances in treating hair loss including the use of lasers with topicals, supplements, or PRP injections. They also discuss some of the risks associated with the use of biotin as a hair growth supplement.Of Sharks and Sunscreen
https://practicaldermatology.com/series/scientifically-speaking/of-sharks-and-sunscreen/20130/Often called on to judge "Shark Tank"-style competitions, Humberto Antunes has an eye for what makes an idea work. He talks with host Joel L. Cohen, MD about ingredients for success and also offers insight on sunscreen access in the US.DermWireTV: USPSTF Tackles Racism; Winlevi Launch; Derm Days in Focus
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-uspstf-tackles-racism-winlevi-launch-derm-days-in-focus/20014/The US Preventive Services Task Force is undertaking efforts to mitigate the influence of systemic racism in its recommendations. Global Psoriasis Day, National Biologics Coordinators Day, and Retinol Day bring attention to skin issues. Sun Pharmaceutical’s Winlevi (clascoterone) cream 1% is now avaStay Relevant with Education
https://practicaldermatology.com/series/dermatology-education-foundation/stay-relevant-with-education/19989/Feed yourself new information and stay on top of data regarding new and existing medications in order to offer patients the best care possible, says Wendy Cantrell, CRNP, DNP. This is particularly important as new understanding of conditions like psoriasis and atopic dermatitis evolve and new treatmNew Topical Options for Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-topical-options-for-psoriasis/19979/Leon Kircik, MD shares his excitement about new molecules for psoriasis. He discusses the available data for tapinarof, a first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, and roflumilast cream, a once-daily topical formulation of roflumilast, a highPediatric Derm: Sunscreen and Insect Repellent Safety
https://practicaldermatology.com/conferences/aad-summer-2021/pediatric-derm-sunscreen-and-insect-repellent-safety/19973/Parents of pediatric dermatology patients often have lots of questions when it comes to sunscreen safety, especially in light of recent headlines about recalls and absorption concerns. Mercedes Gonzalez, MD offers tips for answering these burning questions, including knowing how to discuss availableDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiCOVID-19 Impact: Decisions, decisions: Treating Psoriasis
https://practicaldermatology.com/topics/psoriasis/covid-19-impact-decisions-decisions-treating-psoriasis/19770/Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditiToxin Time: What’s New and Exciting with Neuromodulators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/toxin-time-whats-new-and-exciting-with-neuromodulators/19768/Joel Cohen, MD takes a deep dive into the most recent data on neuromodulators including post-hoc analyses on the potential durability of response. Dr. Cohen also shares updates on Revance’s DAXI, Botox Cosmetic and liquid toxins under development by Galderma and Allergan.